Literature DB >> 29961434

Management of locally advanced T3-4 glottic laryngeal carcinomas.

R Smee1, J R Williams1, D P Kotevski1.   

Abstract

OBJECTIVES: To assess five-year local control and ultimate local control rates of patients treated for locally advanced T3-4 glottic carcinoma with surgery only, radiotherapy only, or surgery plus radiotherapy. Cancer-specific survival, overall survival and rates of malignancy development were also assessed.
METHODS: A retrospective review was conducted on patients from 1967 to 2015, with analysis of local control, ultimate local control, overall survival and cancer-specific survival performed using Kaplan-Meier and Cox regression.
RESULTS: Of 169 eligible patients, the majority (59 per cent) were treated with surgery plus radiotherapy, with laryngectomy being the most common surgical procedure. Local control and ultimate local control rates were higher with surgery only (94.1 per cent) and surgery plus radiotherapy (87.9 and 86.8 per cent respectively), compared to radiotherapy only (46.8 and 52.4 per cent) (both p < 0.001). Cancer-specific survival, overall survival and malignancy development did not differ between groups.
CONCLUSION: Surgery, with or without radiotherapy, offers significantly higher five-year local control and ultimate local control for patients with advanced glottic carcinoma, compared to radiotherapy only.

Entities:  

Keywords:  Glottis; Recurrence; Squamous Cell Carcinoma; TNM Staging; Treatment Outcomes

Mesh:

Year:  2018        PMID: 29961434     DOI: 10.1017/S0022215118000993

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  1 in total

1.  Assessment of cartilage invasion in case of laryngeal cancer by means of longitudinal sectioning for histopathology - Clinical implications.

Authors:  Liucija Weselik; Ewa Majchrzak; Matthew Ibbs; Adam Lewandowski; Andrzej Marszałek; Piotr Machczyński; Wojciech Golusiński
Journal:  Rep Pract Oncol Radiother       Date:  2019-07-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.